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 Paredes et al recently described Poldip2 as a novel regulator of mitochondrial 
lipoylation through stabilisation of ACSM1 (1). We have several concerns with their 
proposed model based on the following reasons. 
Prior mammalian and yeast biochemical studies are not consistent with a significant 
physiological role for lipoate scavenging in eukaryotes (2, 3). Genetic depletion or germline 
mutations in de novo lipoic acid synthesis enzymes (LIAS, LIPT1 and LIPT2) result in loss of 
mitochondrial lipoylation, respiration, and developmental defects in mammals, which are 
not reversed with exogenous lipoic acid (2, 4). While LIPT1 has an established role in this de 
novo synthesis pathway, there is no evidence that LIPT1 is a scavenging enzyme, as implied 
by Paredes et al. The suggestion that all lipoate-dependent enzymes are octanoylated by 
LIPT2 and support LIAS-mediated lipoate synthesis is not, to our knowledge, supported by 
experimental studies.  
ACSM1 is a promiscuous enzyme reported to activate the native (D) and unnatural 
(L) stereoisomers of lipoate in vitro (5). This lack of enantiomeric specificity makes it unlikely 
that ACSM1-catalysed lipoate activation is physiological. Furthermore, as ACSM1 uses GTP 
(5), rather than ATP, it is unclear how ACSM1 would form the lipoyl-AMP intermediate 
proposed in the model by Paredes et al. The authors also provide no explanation as to the 
source of the scavenged lipoate.  
The identification that impaired lipoylation of the 2-oxoglutarate (2-OG) 
dehydrogenase complex (OGDHc) leads to stabilisation of HIF-1⍺, replicates earlier work by 
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Burr et al (6), whereby 2-OG accumulation promotes the formation of L-2-hydroxyglutarate 
(L-2-HG) and inhibition of the prolyl hydroxylases (PHDs) is observed. This activation of HIFs 
following 2-OG and L-2-HG accumulation has been reproducibly observed in hypoxia and 
under acidotic conditions (7, 8). The mechanism proposed by Paredes et al is inconsistent 
with these prior observations. Loss of OGDHc activity leads to an increase in 2-OG levels (6, 
9), rather than the decrease suggested by Paredes et al. Indeed, unbiased metabolomic flux 
studies show LIAS or OGDH deficiency increase cellular 2-OG in both cancer cells and 
primary dermal fibroblasts (6). Moreover, this increase in 2-OG is also observed in humans 
with germline mutations in lipoic acid synthesis (2). Paredes et al use an indirect method to 
measure 2-OG levels and provide no explanation as to why 2-OG levels are reduced in their 
model. More detailed measurements of the metabolic consequences of Poldip2 loss are 
required before concluding that HIF stabilisation is due to decreased 2-OG.  
 Finally, ACSM1 has previously been shown to be depleted in conditions of HIF 
stabilisation such as VHL depletion (10), so it is equally plausible that the loss of ACSM1 in 
hypoxia simply represents its suppression as part of its canonical role in fatty acid beta 
oxidation. 
 
 
 
 
  
 3 
References 
1. Paredes F, et al. (2018) Poldip2 is an oxygen-sensitive protein that controls PDH and 
alphaKGDH lipoylation and activation to support metabolic adaptation in hypoxia 
and cancer. Proceedings of the National Academy of Sciences of the United States of 
America 115(8):1789-1794. 
2. Mayr JA, Feichtinger RG, Tort F, Ribes A, & Sperl W (2014) Lipoic acid biosynthesis 
defects. Journal of inherited metabolic disease 37(4):553-563. 
3. Schonauer MS, Kastaniotis AJ, Kursu VA, Hiltunen JK, & Dieckmann CL (2009) Lipoic 
acid synthesis and attachment in yeast mitochondria. The Journal of biological 
chemistry 284(35):23234-23242. 
4. Habarou F, et al. (2017) Biallelic Mutations in LIPT2 Cause a Mitochondrial 
Lipoylation Defect Associated with Severe Neonatal Encephalopathy. American 
journal of human genetics 101(2):283-290. 
5. Fujiwara K, Takeuchi S, Okamura-Ikeda K, & Motokawa Y (2001) Purification, 
characterization, and cDNA cloning of lipoate-activating enzyme from bovine liver. 
The Journal of biological chemistry 276(31):28819-28823. 
6. Burr SP, et al. (2016) Mitochondrial Protein Lipoylation and the 2-Oxoglutarate 
Dehydrogenase Complex Controls HIF-1alpha Stability in Aerobic Conditions. Cell 
metabolism 24(5):740-752. 
7. Nadtochiy SM, et al. (2016) Acidic pH Is a Metabolic Switch for 2-Hydroxyglutarate 
Generation and Signaling. The Journal of biological chemistry 291(38):20188-20197. 
8. Tyrakis PA, et al. (2016) S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate. 
Nature 540(7632):236-241. 
9. Oldham WM, Clish CB, Yang Y, & Loscalzo J (2015) Hypoxia-Mediated Increases in L-
2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell 
metabolism 22(2):291-303. 
10. Lin Q, et al. (2013) Activation of hypoxia-inducible factor-2 in adipocytes results in 
pathological cardiac hypertrophy. Journal of the American Heart Association 
2(6):e000548. 
 
